Estrogens in reproductive organ tumors

Medycyna Weterynaryjna

Volumn 60, Issue 1, 2004, Pages 6-11

  Madej, Janusz A ^a,b  

^a WROCLAW MEDICAL UNIVERSITY   (Poland)

^b NONE   (Poland)

Author keywords

Estrogens; Induction; Therapy; Tumors

Indexed keywords

BENZOQUINONE; CYCLINE; DNA; ESTROGEN; ESTROGEN RECEPTOR; MYC PROTEIN; PROTEIN C FOS; PROTEIN C JUN; STRESS ACTIVATED PROTEIN KINASE;

CARCINOGENESIS; CELL PROLIFERATION; DNA SYNTHESIS; DRUG EFFECT; FEMALE GENITAL TRACT TUMOR; GENETIC TRANSCRIPTION; HORMONAL THERAPY; MOLECULAR BIOLOGY; NONHUMAN; PROTO ONCOGENE; REVIEW; TREATMENT OUTCOME; TUMOR CELL;

EID: 1442265469     PISSN: 00258628     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (37)

1. Beato M.: Gene regulation by steroid hormons. Cell 1989, 56, 335-339.
2. Cooper E.: Oncogenes. Jones and Bartlett, Boston 1990, 225-229.
3. Conley A., Hinshelwood M.: Mammalian aromatases. Reproduction 2001, 121, 685-695.
4. Darnell J., Lodish H., Baltimore D.: Molecular cell biology. Scientific American Books. 1995, 211-214.
5. Dickson R., McManaway M., Lippman M.: Estrogen-induced factors of breast cancer cells partially replance estrogen to promote tumor growth. Science 1986, 232, 1540-1547.
6. Ewertz M., Schon G., Boice J.: The joint effect of risk factors on endometrial cancer. Europ. J. Cancer Clin. Oncol. 1988, 24, 189-195.
7. Farhi D., Nosanchuk J., Sikverberg S.: Endometrial adenocarcinoma in women under 25 years of age. Obstet. Gynecol. 1986, 61, 966-972.
8. Fujimoto J., Hirose R., Sakagucki H., Tamaya T.: Estrogen dependency in uterine endometrial cancer. Oncology 1998, 55 (supl.), 53-59.
9. Gray L., Christopherson W., Hoover R.: Estrogens and endometrial carcinoma. Obstet. Gynecol. 1977, 49, 385-391.
10. Gurpide E., Fleming H., Holinka C.: Steroid receptors and responsiveness to hormones in endometrial cancer. Hollander V. Academic Press, Orlando 1985, 69-71.
11. Haskell C.: Principles and practice of cancer chemotherapy, [w:] Cancer Treatment. W. Saunders, Philadelphia 1990, 21-29.
12. Jensen E.: Hormone dependency of breast cancer. Cancer, Philad. 1981, 47, 2319-2323.
13. Kacinski B., Chambers S.: Molecular biology of ovarian cancer. Curr. Opin. Oncol. 1991, 3, 889-894.
14. Kaldor J., Day N., Petterson F.: Leukemia following chemiotherapy for ovarian cancer. New Engl. J. Med. 1990, 322, 1-7.
15. Kawiak J., Zabel (red.): Seminaria z cytofizjologii. Wyd. Med. Urban&Partner, Wrocław 2002, 243-253.
16. Konarska L. (red.): Molekularne mechanizmy przekazywania syganłów w komórce. PWN, Warszawa 1995, 65-67.
17. Liu C., Subramaniam M., Rosmussen K.: Rapid inhibition of the c-jun proto-oncogene expression in avian oviduct by estrogen. Endocrynology 1990, 127, 2591-2598.
18. Mack T., Ross R.: Risks and benefits of long-term treatment with estrogens. Schweizer Med. Wschr. 1989, 119, 1811-1817.
19. Murphy L., Murphy L. C., Friesen H.: Estrogen induction of N-myc and c-myc proto-oncogene expression in the rat uterus. Endocrynology 1987, 120, 1882-1888.
20. Nowak J. Z., Zawilska J. B. (red.): Receptory: struktura, charakterystyka, funkcja. PWN, Warszawa 1997, 45-48.
21. Rosenfeld C. S., Yuan X., Manikkam M., Calder M. D., Garverich H. A., Lubahn D. B.: Cloning, sequencing, and localization of bovine estrogen receptor - beta within ovarian follicle. Biol. Reprod. 1999, 60, 691-697.
22. Sasano H., Harada N.: Intratumoral aromatase in human breast, endometrilal and ovarian malignancies. Endocr. Rev. 1998, 19, 593-607.
23. Schmahl D. (red.): Combination effects in chemical carcinogenesis. VCH, Weinheim, Germany 1988, 202-207.
24. Schwartz P., Chambers J., Kohorn E.: Tamoxifen in combination with cytotoxic chmiotherapy in advanced epithelial ovarian cancer: a prospective randomized trial. Cancer, Philad. 1989, 36, 1074-1079.
25. Schwartz P., Merino M., Livalsi V.: Histopathologic correlations of estrogen and progestin receptor protein in epithelial ovarian carcinomas. Obstet. Gynecol. 1985, 66, 428-431.
26. Shafie S., Brooks S. C.: Effect of prolactin on growth and the estrogen receptor level of human breast cancer calls (MCF - 7). Cancer Res. 1997, 37, 792-799.
27. Słomczyńska M.: Receptory hormonów steroidowych - budowa i funkcja. Post. Biol. Kom. 1995, 22, 3-21.
28. Spaczyński M. (red.): Onkologia ginekologiczna. Wyd. Med. Urban&Partner, Wrocław 1997, 99-101.
29. Spesberg T., Rories C., Rejman J.: Steroid action on gene expression: possible roles of regulatory genes and nuclear acceptor sites. Biology Reprod. 1989, 40, 54-59.
30. Subramaniam M., Rasmussen K., Spelsberg T.: Rapid down regulation of c-jun proto-oncogene transcription in avian oviduct by progesterone. J. Cell Biol. 1990, 102, 111-115.
31. Tkaczyk M., Kalita K.: Receptor estrogenowy beta - budowa, regulacja i funkcja. Post. Biochem. 2001, 47, 72-79.
32. Webbe D., Moulton E., Khan S.: Estrogen induced expression of the c-jun proto-oncogene in the immature and mature rat uterus. Biochem. biophys. Res. Commun. 1990, 168, 721-727.
33. Wentz W:. Progestin therapy in lesions of the endomtrium. Seminar. Oncology 1985, 12, 23-27.
34. Whitehead M., Fraser D.: The effect of estrogens and progretogenes on the endomatrium: modern approach to treatment. Obstet. Gynecol. Clin. North Am. 1987, 14, 299-307.
35. Wójcik C., Wójcik M.: Niebialkowe inhibitory kinaz zależnych od cyklin. Post. Biol. Kom. 2000, 27, 377-386.
36. Young R.: Initial therapy for early ovarian carcinoma. Cancer, Philad. 1987, 60, 2042-2046.
37. Zhang H., Somasundaram K., Peng Y., Tian H., Bi D., Weber B. L., El-Diery W. S.: BRAC 1 physically associates with p53 and stimulates its transcriptional activaty. Oncogene 1998, 16, 1713-1721.